Aktis Oncology Inc (AKTS) is now in the Overvalued zone, suggesting that its current forward PS ratio of 0.02 is considered Overvalued compared with the five-year average of -5.38. The fair price of Aktis Oncology Inc (AKTS) is between -7331.08 to -7331.08 according to relative valuation method. Compared to the current price of 20.00 USD , Aktis Oncology Inc By Overvalued By -100.27%.

Relative Value

Fair Zone

-7331.08--7331.08

Current Price：20.00

-100.27%

Overvalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Aktis Oncology Inc (AKTS) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Aktis Oncology Inc (AKTS) has a current Price-to-Book (P/B) ratio of -0.02. Compared to its 3-year average P/B ratio of 0.92, the current P/B ratio is approximately -101.68% higher. Relative to its 5-year average P/B ratio of 2.24, the current P/B ratio is about -100.69% higher. Aktis Oncology Inc (AKTS) has a Forward Free Cash Flow (FCF) yield of approximately -4120.76%. Compared to its 3-year average FCF yield of -193.63%, the current FCF yield is approximately 2028.18% lower. Relative to its 5-year average FCF yield of -102.82%, the current FCF yield is about 3907.75% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for AKTS competitors is -35.91, providing a benchmark for relative valuation. Aktis Oncology Inc Corp (AKTS.O) exhibits a P/S ratio of --, which is -100% above the industry average. Given its robust revenue growth of 28.92%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of AKTS increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of AKTS in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is AKTS currently overvalued or undervalued?

What is Aktis Oncology Inc (AKTS) fair value?

AKTS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Aktis Oncology Inc (AKTS) is between -7331.08 to -7331.08 according to relative valuation method.

How does AKTS's valuation metrics compare to the industry average?

The average P/S ratio for AKTS's competitors is -35.91, providing a benchmark for relative valuation. Aktis Oncology Inc Corp (AKTS) exhibits a P/S ratio of --, which is -100.00% above the industry average. Given its robust revenue growth of 28.92%, this premium appears sustainable.

What is the current P/B ratio for Aktis Oncology Inc (AKTS) as of Mar 02 2026?

As of Mar 02 2026, Aktis Oncology Inc (AKTS) has a P/B ratio of -0.02. This indicates that the market values AKTS at -0.02 times its book value.

What is the current FCF Yield for Aktis Oncology Inc (AKTS) as of Mar 02 2026?

As of Mar 02 2026, Aktis Oncology Inc (AKTS) has a FCF Yield of -4120.76%. This means that for every dollar of Aktis Oncology Inc's market capitalization, the company generates -4120.76 cents in free cash flow.

What is the current Forward P/E ratio for Aktis Oncology Inc (AKTS) as of Mar 02 2026?

As of Mar 02 2026, Aktis Oncology Inc (AKTS) has a Forward P/E ratio of -0.02. This means the market is willing to pay $-0.02 for every dollar of Aktis Oncology Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Aktis Oncology Inc (AKTS) as of Mar 02 2026?

As of Mar 02 2026, Aktis Oncology Inc (AKTS) has a Forward P/S ratio of 0.02. This means the market is valuing AKTS at $0.02 for every dollar of expected revenue over the next 12 months.

AKTS Valuation